Alkermes reports positive Phase 1b proof-of-concept results for ALKS 7290 in adult ADHD

Alkermes reported positive topline Phase 1b results for ALKS 7290, showing dose-dependent, clinically meaningful improvements on exploratory ADHD symptom measures in adults, demonstrating clinical proof-of-concept. The company said the study was not powered for statistical significance on those exploratory endpoints.

Detected & updated continuously · Source: Nebula